CAMBRIDGE, England–(BUSINESS WIRE)–Amphista Therapeutics Limited (‘Amphista’ or ‘the Company’), a clinical-stage biopharmaceutical company focused on the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced new data on its lead therapeutic candidate, AMX-883, has been accepted for oral presentation at American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15, 2026. The full abstract is available online: www.hema